McGill Univ spinoff Mimetogen Pharmaceuticals Inc has received series A financing from a venture capital consortium led by Boston-based VIMAC Milestone Medica Fund. Also participating is original investor MSBi Capital, a seed and early-stage fund created to commercialize technologies from McGill, Univ of Sherbrooke and Bishop's Univ. Mimetogen is currently developing therapeutic approaches for small cell lung cancer and glaucoma. Its technology is based on 10 years of R&D at McGill and its affiliated Lady Davis Institute for Medical Research. Mimetogen recently appointed Dr Garth Cumberlidge as its president and CEO....
Other stories mentioning these organizations, people and topics
| Organizations: | Bishop's Univ, Lady Davis Institute for Medical Research, McGill Univ, Mimetogen Pharmaceuticals Inc, Univ of Sherbrooke, and VIMAC Milestone Medica Fund |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.